Browse the evidence

Peripheral GLP-1 signaling is not essential for long-term energy balance or bodyweight regulation in humans or rodents, as evidenced by normal body weight in GLP-1R knockout mice and lack of effect from peripheral antagonism.

Your body's natural production of GLP-1 in the gut does not significantly control your long-term weight. This is why lifestyle changes alone often fail to sustain weight loss, and why pharmacologic doses that strongly activate brain receptors are needed for significant weight reduction.

GLP-1 receptor internalization is arrestin-independent and relies on a dual mechanism involving Gs/Gi/o protein activation, GRK phosphorylation, and both clathrin- and caveolae-mediated endocytosis.

This research clarifies that GLP-1 drugs work by engaging specific cellular recycling pathways (clathrin and caveolae) rather than the arrestin pathway. This mechanistic insight aids in designing drugs with optimized duration and fewer side effects, though it does not change immediate patient behavior.

Circulating IGF-1 concentrations are not associated with all-cause, cardiovascular disease, or cancer-related mortality risk.

There is no evidence from this study that your natural IGF-1 levels predict your risk of death from cancer, heart disease, or other causes. You do not need to try to manipulate IGF-1 levels for longevity based on this data.

Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.

This paper describes a rare genetic condition (myostatin deficiency) that causes massive muscle growth. For the average person, this is not a viable or safe intervention. However, understanding that myostatin limits growth suggests that therapies blocking it (under medical supervision) might help those with muscle-wasting diseases, but it is not a recommendation for healthy individuals seeking hypertrophy.

Semaglutide does not significantly impact renal outcomes, including nephrolithiasis, acute kidney injury, or chronic kidney disease, in patients with overweight or obesity.

If you are using semaglutide for weight management or cardiovascular risk reduction, do not expect it to protect your kidneys. This meta-analysis found no significant impact on renal outcomes like kidney stones or acute kidney injury in overweight or obese patients.

Pharmacological inhibition of Complement C3 using AMY-101 improves healthspan, metabolic fitness, and reduces inflammaging in aged mice.

In aged mice, weekly injections of a C3 inhibitor (AMY-101) improved metabolic health and physical function. This suggests that targeting the complement system could be a viable strategy to combat age-related decline, potentially mimicking the benefits of caloric restriction.

Age-associated elevation of C3a in visceral adipose tissue (VAT) is primarily driven by adipose tissue macrophages (ATMs) via an autocrine ERK-dependent signaling loop.

In aging, fat tissue (specifically visceral fat) becomes a source of inflammation due to immune cells (macrophages) producing complement proteins like C3a. This process is driven by specific signaling pathways within these cells.

Obesity heritability is estimated at 40-70%, driven by over 1000 genetic variants and complex interactions with environmental and epigenetic factors, with early-onset severe obesity strongly linked to specific genetic mutations.

Recognize that obesity has a strong biological basis, with heritability estimates up to 70%. For those with early-onset severe obesity, genetic factors play a major role. This understanding supports the use of targeted therapies and early screening rather than relying solely on lifestyle advice.

Chronic hyperglycemia and oxidative stress induce beta-cell dedifferentiation by altering the balance of PAX4 and ARX gene expression, causing beta-cells to lose insulin-secreting identity and adopt alpha-cell features.

In Type 2 Diabetes, high blood sugar and stress can cause insulin-producing beta-cells to 'forget' their job and turn into glucagon-producing alpha-like cells. This is driven by epigenetic changes to genes like PAX4 and ARX. This loss of identity contributes to worsening blood sugar control, suggesting that therapies aiming to restore beta-cell identity or function could be beneficial.

Tirzepatide attenuates alcohol-induced dopamine release in the nucleus accumbens and induces sustained synaptic depression in the lateral septum.

Tirzepatide's effect on alcohol reward involves reducing dopamine release in the nucleus accumbens and altering synaptic plasticity in the lateral septum.

Genetically predicted higher childhood obesity, adult obesity, and increased fat-free mass are causally associated with a reduced risk of Brugada syndrome.

If you have Brugada syndrome, maintaining a BMI in the upper-normal range and increasing fat-free mass through resistance training may help reduce your risk. This contrasts with general population advice to lose weight, so consult your cardiologist about personalized weight management.

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

Adjunctive semaglutide therapy significantly enhances total body weight loss and prevents post-balloon weight regain compared to intragastric balloon (IGB) alone in patients with BMI ≥ 27 kg/m².

If you are using an intragastric balloon for weight loss, adding semaglutide (a GLP-1 medication) can significantly increase your total weight loss and help you keep the weight off after the balloon is removed. The study used a specific dosing schedule starting at 0.5mg and going up to 1mg weekly, pausing while the balloon is in place, and restarting after removal. This approach helps overcome the natural weight regain that often happens after balloon removal alone.

In patients with overweight or obesity without type 2 diabetes, 1-year treatment with semaglutide 2.4 mg or tirzepatide results in clinically meaningful weight loss of 14.1% and 16.5%, respectively, in real-world clinical practice.

If you have obesity or are overweight and do not have type 2 diabetes, treatment with semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) for one year in a real-world setting leads to significant weight loss, averaging 14-16% of body weight. This effectiveness holds true in routine clinical practice, not just in clinical trials, although reaching the maximum dose is not guaranteed for everyone.

Adjuvant semaglutide at lower doses (≤1 mg/week) achieves clinically significant weight loss (median 7.5% TWL) in post-bariatric surgery patients with refractory obesity, with a favorable side effect profile compared to higher doses.

If you have had bariatric surgery and are experiencing weight regain or insufficient loss, ask your doctor about adjuvant semaglutide. You may not need the highest dose (2.4 mg); many patients achieve significant weight loss (around 7.5% of total body weight) at lower doses (1 mg or less). This approach is often more affordable, has fewer side effects, and is sufficient for long-term management, especially if supply of higher doses is an issue.

Post-bariatric patients with insufficient weight loss or weight regain achieve significant additional weight loss and comorbidity improvement when treated with GLP-1 receptor agonists (semaglutide or dulaglutide).

If you have had bariatric surgery and are not losing enough weight or are gaining it back, ask your doctor about GLP-1 medications like semaglutide or dulaglutide. These drugs can help you lose more weight and improve health conditions like high blood pressure and sleep apnea. They are taken as weekly injections and are generally well-tolerated, though nausea is a common side effect.

Subcutaneous semaglutide (starting 0.25 mg, titrated to 1 mg weekly) significantly reduces body weight and HbA1c in patients with type 2 diabetes, with maximal efficacy observed when combined with lifestyle modifications (diet and exercise).

If you have Type 2 Diabetes, semaglutide (Ozempic) is an effective tool for losing weight and lowering blood sugar. To get the best results, take it as prescribed (starting low and building up) and combine it with a healthy diet and regular exercise. Be aware that stomach issues like nausea are common reasons people stop taking it, so talk to your doctor about managing these side effects to stay on the medication.

Semaglutide (both injectable and oral formulations) induces significant weight loss and maintains weight loss over 12-24 months in patients with type 2 diabetes and obesity/overweight.

If you have type 2 diabetes and are overweight or obese, semaglutide (either as a weekly injection or daily pill) can help you lose a significant amount of weight and keep it off for at least a year. It works best when combined with a moderate calorie-reduced diet and regular walking. Both forms are effective, so you can choose based on your preference for injections vs. pills.

CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, produces clinically meaningful weight loss (4.7% to 8.0% over 4 weeks) and improved glycemic control in participants with overweight or obesity, with a safety profile consistent with other incretin-based therapies.

CT-388 is a once-weekly injection that helps people with overweight or obesity lose weight (4.7% to 8.0% in 4 weeks) and improves blood sugar control. It is generally well-tolerated, with most side effects being mild or moderate. This makes it a promising option for treating obesity and type 2 diabetes, though long-term data is still needed.

GZR18, a GLP-1 receptor agonist administered once-weekly or bi-weekly, induces robust body weight reductions (up to 17.8%) and improves metabolic parameters in Chinese adults with overweight or obesity.

GZR18 is a once-weekly or bi-weekly GLP-1 injection that helps overweight or obese Chinese adults lose significant weight (up to 17.8%) and improve metabolic health. It is designed to minimize side effects like nausea, making it a potentially tolerable option for those who struggle with frequent injections or severe gastrointestinal issues from other GLP-1 drugs. Consult a doctor to see if it's appropriate for you.